Galaxy Balance

About Galaxy Balance

Galaxy Balance explores the frontier where biology, technology and consciousness meet. Each episode brings together pioneers shaping our collective future, from genome engineers and AI builders to longevity researchers, space explorers, and mindfulness practitioners. Hosted by Cory Smith, the conversations dive deep into how these seemingly distant fields form an interconnected ecosystem, one that balance innovation with introspection, science with spirit, and ambition with awareness. At its core, Galaxy Balance is about integration; the idea that our greatest leaps forward happen when disciplines collide. The same algorithms that decode galaxies can help us understand genomes; the same principles that govern consciousness can illuminate AI. Through long-form, unscripted dialogue, the show invites listeners to zoom out from the silos of specialization and see the larger pattern: a living system of intelligence evolving across scales – molecular, planetary, and cosmic.

Publisher

Cory Smith

Category

science

Language

en

Explicit

No

First episode

10 Dec 2025

Latest episode

23 Sept 2026

Latest episodes

28 episodes in the feed.

1. 

   23 Sept 2026

   Can We Build Virus-Proof Life?

   What happens when scientists rewrite the genetic code that nearly all life on Earth shares? Dr. Akos Nyerges, a genome engineer and independent research group leader at Harvard Medical School, joins Galaxy Balance to explore the emerging world of synthetic genomes. His lab is engineering bacteria with altered genetic codes that can resist viral infection, restrict the exchange of genetic information, and incorporate chemical building blocks beyond biology’s standard 20 amino acids. Akos explains how these genetic firewalls could make engineered organisms safer for drug delivery, biomanufacturing, and environmental applications. We examine why large-scale genome rewriting often produces sick cells, how multi-omics can reveal hidden errors such as accidental promoters and mistranslated proteins, and how his team restored recoded bacteria to near-normal fitness. The conversation also explores AI-assisted genome design, cloud laboratories, engineered living medicines, horizontal gene transfer, the risks of mirror life, and the regulatory frameworks needed as synthetic biology moves toward increasingly ambitious forms of life. Could we create organisms isolated from the rest of nature? Can evolution overcome even our strongest genetic firewalls? And how close is modern genome engineering to becoming science fiction made real? 00:00 Introduction 01:16 Akos’s Path to Synthetic Biology 03:59 Engineering the Genetic Code 05:45 Three Goals for Synthetic Biology 09:16 Controlling Horizontal Gene Transfer 11:11 Building a Genetic Firewall 13:39 Toxicity of Recoded tRNAs 14:26 Drug Delivery and Bioremediation 16:22 Solving the Fitness Problem 18:35 Measuring Real Biological Fitness 20:13 Testing Virus Resistance 23:37 Why the Genetic Code Is Universal 26:42 From Recoding to Applications 28:52 Debugging Genomes With Multiomics 31:15 Hidden Bugs in Genome Design 35:33 AI for Genome Design 37:51 Can LLMs Recode Genomes? 40:06 Building Local AI Compute 42:18 Cloud Labs and CROs 45:52 From Lab to Commercial Use 47:26 Translational Research and IP 48:44 Expanding Biology’s Chemical Alphabet 49:59 Ethics, Biosafety, and Regulation 53:23 The Risks of Mirror Life 57:37 When Science Fiction Becomes Real 58:33 Closing and Hiring Announcement

2. 

   7 Sept 2026

   Humanity May Become the Little Green Men

   If the universe contains billions of potentially habitable worlds, where is everybody? Dr. Terry Adair, author of Where Are the Little Green Men? The Adair Hypothesis, joins Galaxy Balance to examine the Fermi paradox through the lens of energy. His hypothesis proposes that an advanced technological civilization requires access to an abundant, dense, storable, transportable, and scalable energy supply. The conversation traces Earth’s energetic evolution from hydrothermal chemistry and photosynthesis to fire, fossil fuels, nuclear fission, and fusion. Terry explains how photosynthesis enabled complex life while also creating the ancient reserves of coal, oil, and natural gas that eventually powered industrial civilization. He argues that this unlikely sequence may represent a series of filters preventing intelligent life elsewhere from producing detectable technology or reaching other stars. We also explore the Drake equation, abiogenesis, the evolution of complex life, the technological limitations of ocean worlds, the challenges surrounding red dwarf stars, and the laws of thermodynamics that constrain every possible civilization. Terry outlines how fusion energy could eventually enable plasma drives, antimatter production, and spacecraft capable of reaching a meaningful fraction of the speed of light. The episode closes with an optimistic vision of humanity’s long-term future. If we continue expanding our scientific knowledge and energy capabilities, humans may eventually become the interstellar visitors that other civilizations look toward the sky hoping to find. 00:00 - Why the Fermi paradox belongs at the center of this conversation 03:37 - How Adair’s background led him to an energy-based hypothesis 04:20 - What the Fermi paradox actually means 08:14 - Drake equation, exoplanets, and the Great Filter 10:23 - Why the Drake equation is a framework, not an exact answer 11:47 - Why abiogenesis and intelligence are not the same question 13:29 - Earth’s evolutionary milestones from microbes to technology 15:10 - Why photosynthesis is the breaking point in life’s history 18:28 - The difference between abundant energy and usable energy 21:49 - Endosymbiosis, mitochondria, and the energy jump in complex life 23:51 - Why CO2 is the raw material behind plant structure 26:19 - How biomass became coal, oil, and natural gas 29:25 - Where uranium and thorium come from 31:46 - Why nuclear fusion is central to future civilization 33:34 - Entropy, disorder, and why perpetual motion fails 38:03 - The limits of fossil fuels and the case for nuclear fission 40:02 - Weapons, waste, and why small modular reactors matter 43:20 - The Adair Hypothesis, defined 44:14 - Fire as humanity’s first technology 47:27 - The photosynthetic trap and why fossil fuels changed civilization 49:58 - How much energy humanity has burned in 200 years 51:21 - Could an aquatic species build technology without fire? 52:32 - From Democritus to quarks: what matter really is 56:22 - Why energy access on Earth is still an equity issue 58:51 - Antimatter, plasma drives, and propulsion limits 62:47 - Why fusion-powered travel is a 300 to 400 year project 64:21 - Humans as the future “little green men” 65:21 - Why Star Wars is Adair’s favorite science fiction reference

3. 

   24 Aug 2026

   Can We Make a Drug for One Person?

   What if we could design a medicine for a single person? Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter. Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind. We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients. We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them. Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized? 00:00 - Casey McPherson’s path from musician to biotech founder 01:38 - Childhood curiosity: music, programming, electronics, and biology 04:16 - Rose’s diagnosis and the end of the traditional care pathway 07:46 - Learning the problem was bigger than one child 09:59 - Why a foundation and ecosystem had to come first 11:27 - Why Rare Labs was built as a modality agnostic discovery lab 12:24 - Why antisense oligonucleotides made sense for Rose 13:22 - Designing and filtering thousands of ASO candidates 15:13 - Building patient-specific iPSCs and brain organoids 17:25 - Why animal models are mainly a safety tool 20:06 - Why Alpha Rose became a public benefit corporation 23:22 - Regulatory strategy and the path toward a small patient trial 27:35 - How Casey learned drug development by doing 30:30 - The AI amenability study workflow for new patients 33:24 - Turning a rough AI prototype into a validated internal tool 35:34 - Using the tool on every new drug and patient case 36:31 - Why speed matters when families are waiting on treatment 37:54 - Rare disease as a business model problem, not just a science problem 43:02 - The next decade of individualized medicine 44:27 - Process approval and point-of-care drug synthesis 46:34 - Beyond rare disease: enhancement and broader applications 48:24 - Why children’s health is so underfunded 51:20 - Why precision medicines can lower development risk 53:33 - Robotics and the fully automated lab of the future 55:46 - Renee, conversational AI, and the scientist-as-assistant future 56:54 - Science fiction influence and the Star Trek medicine model 59:50 - Advice for families and scientists facing genetic disease 1:02:21 - Closing thoughts on individualized disease

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

3 ratings

Spotify

5.0 / 5

3 ratings

Contact Galaxy Balance

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.